Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.70 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.63 |
| ▸ | CDK9 | P50750 | 3/20 | 0.61 |
| ▸ | CCNK | O75909 | 2/20 | 0.61 |
| ▸ | CCND3 | P30281 | 2/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.61 |
| ▸ | NEK2 | P51955 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883224 | 0.91 | BRD4 (0.61) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL1885127 | 0.91 | BRD4 (0.60) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL25068846 | 0.85 | CDK9 (0.82) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL1895667 | 0.83 | BRD4 (0.49) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL18757714 | 0.82 | BRD4 (1.00) | BRD4ALKJAK2JAK3 | |
| SCHEMBL1606982 | 0.81 | BRD4 (0.69) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL1880046 | 0.81 | ALK (0.54) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL1884694 | 0.81 | BRD4 (0.49) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL1878922 | 0.80 | ALK (0.49) | BRD4ALKCDK9CCNKCCND3 | |
| SCHEMBL18757993 | 0.77 | BRD4 (0.84) | BRD4ALKJAK2RETWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | BRD4 2500/4885ALK 707/4885CDK9 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.